Antonius van Dijk - 09 Jan 2023 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Role: Chief Scientific Officer
Signature: By: /s/ Christine Klaskin, Attorney-in-Fact for Marcus Antonius van Dijk
Issuer symbol: INKT
Transactions as of: 09 Jan 2023
Transactions value $: $63,482
Form type: 4
Filing time: 12 Jan 2023, 09:48:51 UTC
Previous filing: 25 Jan 2022
Next filing: 18 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INKT	Common Stock	Award	$119,776	+51,628		$2.32	51,628	09 Jan 2023	Direct	F1, F2
transaction	INKT	Common Stock	Tax liability	-$56,294	-24,265	-47%	$2.32	27,363	09 Jan 2023	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the executive's 2022 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 50% of the award released on March 24, 2023 and 50% of the award released on June 24, 2023.
F2	$2.32 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 9, 2023, the stock issuance date.
F3	Represents payment of tax liability by withholding shares of common stock incident to the vesting of stock.